GENE ONLINE|News &
Opinion
Blog

2020-12-18| Asia-PacificR&D

NASH Drug Candidate, ASC42 Receives Fast Track Designation

by GeneOnline
Share To

A Non-Alcoholic Steatohepatitis (NASH) drug candidate ASC42, a Farnesoid X Receptor (FXR) Agonist from Gannex, received Fast Track designation from the U.S. Food and Drug Administration (FDA) on 14th December 2020.

The U.S. FDA’s Fast track is a process designed to facilitate new drug development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Its purpose is to get important new drugs to the patient earlier. This Fast Track designation represents the FDA’s recognition of ASC42’s potential in addressing these unmet medical needs for NASH patients.

 

Regulatory History of ASC42

Gannex is a wholly-owned company of Ascletis Pharma Inc. and fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex received the investigational new drug application (IND) approval for ASC42 from the U.S. FDA in October this year. ASC42 is an in-house developed, novel non-steroidal, selective, potent FXR agonist with best-in-class potential. In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation, and fibrosis. The oral tablet formulation of ASC42 has been developed with in-house proprietary technology and is stable at room temperature.

 

NASH

NASH is a progressive liver disease caused by excessive accumulation of fat in the liver. It can cause chronic inflammation in the liver, trigger progressive liver fibrosis, cirrhosis, and ultimately lead to liver failure, cancer, and patient death. The liver-related mortality in patients with advanced fibrosis is significantly increased. However, there are no FDA approved medicines for NASH indication yet.

At present, NASH is predicted to be one of the largest drug markets in the field of drug treatment for liver diseases after hepatitis C. It is estimated that the global NASH therapeutic drug market will reach US$ 40 billion in 2025. In addition to Gannex’s ASC42, Potential drugs with rapid progress in clinical research include, e.g., GENFIT’s PPAR receptor agonist Elafibranor, Intercept’s farnesol receptor (FXR) agonist obeticholic acid (OCA), Allergan’s CCR2/CCR5 chemokine receptor blocker Cenicriviroc (CVC), Gilead’s anti-apoptotic signal-regulating kinase 1 (ASK1) inhibitor Selonsertib, and Inventiva’s pan-PPAR agonist Lanifibranor.

Related Article: Gilead and Novo Nordisk Present Proof-of-Concept Data for the First Possible NASH Treatment

Partner Article, By James Hou, Ph.D.

 

 

References
  1. https://www.ascletis.com/news_detail/172/id/443.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
2022-11-15
The FDA Expands Use for Gilead Science’s HBV Treatment
2022-11-02
Santhera, ReveraGen’s Duchenne Drug Accepted By EMA While Anticipating FDA Priority Review
2022-11-01
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!